Dr. Reddy's Laboratories reports its Q4 FY2026 results on May 8 with one acute question dominating the setup: can the generic semaglutide opportunity translate into the kind of top-line momentum the stock needs to reverse a month of grinding underperformance?
Short interest has eased noticeably in the lead-up to the print, removing one obvious source of pressure. Estimated shorts fell roughly 8.8% over the past week to around 13.8 million shares. The official FINRA reading as of the mid-April settlement date put days-to-cover at 5.5, and the ORTEX daily estimate now has that running to 8.6 — elevated, but in the context of a declining position rather than a building one. The borrow market tells a subtler story: cost-to-borrow has climbed 40% in a week to 0.78% — modest in absolute terms, but the direction of travel is upward. Availability has tightened in recent days, with utilization jumping from the mid-50s to 75.7% — still well off its 52-week peak of 90.4%, so no meaningful squeeze pressure exists yet. Overall, positioning looks cautious rather than combative: shorts are covering, not piling in.
The options market is arguably the more pointed signal. The put/call ratio of 0.07 is running below its 20-day mean and sits near the low end of its one-year range — a picture of call-heavy positioning that reflects investors leaning into upside scenarios rather than hedging against a miss. That tilt is notable given a stock that is down about 1% on the month and only fractionally positive over the past week at $13.72. The recent Canadian approval of Dr. Reddy's generic semaglutide injection is the most concrete near-term catalyst, with multiple outlets confirming Health Canada's clearance in late April. The question the print will answer is how much of that pipeline conversion is already priced into the options skew.
The institutional ownership picture is broadly stable. Indian domestic funds — ICICI Prudential, LIC, PPFAS — remain anchored around major positions, collectively holding over a quarter of outstanding shares. BlackRock added roughly 375,000 shares as of end-March, and Boston Partners nearly doubled its exposure with a 4-million-share addition. That incremental global institutional buying into weakness provides a constructive backdrop, even as the two founding family holders — Kallam Reddy and Gunupati Prasad — have been trimming positions modestly. Insider activity overall has been dormant since July 2025. The last material trade on record was CEO Erez Israeli's $5.25 million sale in August 2024, meaning there is no fresh signal from the C-suite to lean on.
The EV/EBITDA multiple of 13.6x has eased fractionally over the past week, with a P/E near 23.4x. The dividend score ranks in the 91st percentile. Both suggest a stock the market treats as fundamentally sound but not aggressively priced for a catalyst. The earnings surprise score sits at the 60th percentile — slightly above average — which means history supports beats without predicting one. Recent quarterly reporting across India's pharma sector has drawn mixed commentary, with revlimid genericisation headwinds flagged as a drag, making the revenue composition of the Q4 release the most direct test of whether the pipeline diversification story is advancing fast enough to offset legacy generic erosion.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
